Pediatric Sleep Pharmacology

Schnoes, 2006, Pediatric prescribing practices for clonidine and other pharmacologic agents for children with sleep disturbance, Clin Pediatr (Phila), 45, 229, 10.1177/000992280604500304 Owens, 2003, Medication use in the treatment of pediatric insomnia: Results of a survey of community-based pediatricians, Pediatrics, 111, e628, 10.1542/peds.111.5.e628 Stojanovski, 2007, Trends in medication prescribing for pediatric sleep difficulties in US outpatient settings, Sleep, 30, 1013, 10.1093/sleep/30.8.1013 Pelayo, 2004, Pediatric sleep pharmacology: You want to give my kid sleeping pills?, Pediatr Clin North Am, 51, 117, 10.1016/S0031-3955(03)00179-2 Zito, 2000, Trends in the prescribing of psychotropic medications to preschoolers, JAMA, 283, 1025, 10.1001/jama.283.8.1025 2005 Morgenthaler, 2006, Practice parameters for behavioral treatment of bedtime problems and night wakings in infants and young children, Sleep, 29, 1277 Morgenthaler, 2006, Practice parameters for the psychological and behavioral treatment of insomnia: An update, Sleep, 29, 1415, 10.1093/sleep/29.11.1415 Wyatt, 2004, Delayed sleep phase syndrome: Pathophysiology and treatment options, Sleep, 27, 1195, 10.1093/sleep/27.6.1195 Chesson, 1999, Practice parameters for the use of light therapy in the treatment of sleep disorders, Sleep, 22, 641, 10.1093/sleep/22.5.641 Johnson, 2006, Ramelteon: A novel hypnotic lacking abuse liability and sedative adverse effects, Arch Gen Psychiatry, 63, 1149, 10.1001/archpsyc.63.10.1149 Stigler, 2006, Ramelteon for insomnia in two youths with autistic disorder, J Child Adolesc Psychopharmacol, 16, 631, 10.1089/cap.2006.16.631 1996 Kay, 2000, The effects of antihistamines on cognition and performance, J Allergy Clin Immunol, 105, S622, 10.1067/mai.2000.106153 Duke, 1998, Case 1 presentation of bizarre behaviors, Pediatr Rev, 19, 245 Russo, 1976, The effectiveness of diphenhydramine HCI in pediatric sleep disorders, J Clin Pharmacol, 16, 284, 10.1002/j.1552-4604.1976.tb02406.x Baker, 2003, Fatal diphenhydramine intoxication in infants, J Forensic Sci, 48, 425, 10.1520/JFS2002121 2002, Labeling of diphenhydramine-containing drug products for over-the-counter human use, Fed Regist, 67, 72555 Bender, 2001, Children's school performance is not impaired by short-term administration of diphenhydramine or loratadine, J Pediatr, 138, 656, 10.1067/mpd.2001.112647 Yanai, 1995, Histamine H1 receptor occupancy in human brains after single oral doses of histamine H1 antagonists measured by positron emission tomography, Br J Pharmacol, 116, 1649, 10.1111/j.1476-5381.1995.tb16386.x Tashiro, 2002, Roles of histamine in regulation of arousal and cognition: Functional neuroimaging of histamine H1 receptors in human brain, Life Sci, 72, 409, 10.1016/S0024-3205(02)02276-2 Gengo, 1989, The pharmacodynamics of diphenhydramine-induced drowsiness and changes in mental performance, Clin Pharmacol Ther, 45, 15, 10.1038/clpt.1989.3 Albert, 1975, Pharmacokinetics of diphenhydramine in man, J Pharmacokinet Biopharm, 3, 159, 10.1007/BF01067905 Merenstein, 2006, The trial of infant response to diphenhydramine: The TIRED study—A randomized, controlled, patient-oriented trial, Arch Pediatr Adolesc Med, 160, 707, 10.1001/archpedi.160.7.707 Dinndorf, 1998, Risk of abuse of diphenhydramine in children and adolescents with chronic illnesses, J Pediatr, 133, 293, 10.1016/S0022-3476(98)70240-9 Nigro, 1975, Sleep: Notes on pediatric pharmacotherapy (in the light of current knowledge of its principal characteristics), Minerva Pediatr, 27, 1999 Pershad, 1999, Chloral hydrate: The good and the bad, Pediatr Emerg Care, 15, 432, 10.1097/00006565-199912000-00018 Loewy, 2006, Sleep/sedation in children undergoing EEG testing: a comparison of chloral hydrate and music therapy, Am J Electroneurodiagnostic Technol, 46, 343, 10.1080/1086508X.2006.11079593 Haydon, 2001, Are second-generation antihistamines appropriate for most children and adults?, Arch Otolaryngol Head Neck Surg, 127, 1510, 10.1001/archotol.127.12.1510 Meltzer, 1991, Comparative safety of H1 antihistamines, Ann Allergy, 67, 625 Corey, 2000, Nasal congestion: A review of its etiology, evaluation, and treatment, Ear Nose Throat J, 79, 690, 10.1177/014556130007900908 Touitou, 2001, Human aging and melatonin, Exp Gerontol, 36, 1083, 10.1016/S0531-5565(01)00120-6 Wagner, 1998, Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia, Ann Pharmacother, 32, 680, 10.1345/aph.17111 Buscemi, 2006, Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: Meta-analysis, BMJ, 332, 385, 10.1136/bmj.38731.532766.F6 Jan, 2001, Melatonin replacement therapy in a child with a pineal tumor, J Child Neurol, 16, 139, 10.1177/088307380101600215 Smits, 2001, Melatonin for chronic sleep onset insomnia in children: A randomized placebo-controlled trial, J Child Neurol, 16, 86, 10.1177/088307380101600204 Weiss, 2006, Sleep hygiene and melatonin treatment for children and adolescents with ADHD and initial insomnia, J Am Acad Child Adolesc Psychiatry, 45, 512, 10.1097/01 Van der Heijden, 2007, Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia, J Am Acad Child Adolesc Psychiatry, 46, 233, 10.1097/01.chi.0000246055.76167.0d Ingrassia, 2005, The use of clonidine for severe and intractable sleep problems in children with neurodevelopmental disorders—A case series, Eur Child Adolesc Psychiatry, 14, 34, 10.1007/s00787-005-0424-4 Ashton, 1994, Guidelines for the rational use of benzodiazepines, Drugs, 48, 25, 10.2165/00003495-199448010-00004 Wills, 2002, Parasomnias: Epidemiology and management, CNS Drugs, 16, 803, 10.2165/00023210-200216120-00002 Salva, 1995, Clinical pharmacokinetics and pharmacodynamics of zolpidem, Clin Pharmacokinet, 29, 142, 10.2165/00003088-199529030-00002 Weitzel, 2000, Zaleplon: A pyrazolopyrimidine sedative-hypnotic agent for the treatment of insomnia, Clin Ther, 22, 1254, 10.1016/S0149-2918(00)83024-6 Zammit, 2006, Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening, J Clin Sleep Med, 2, 417, 10.5664/jcsm.26657 Blumer, 2008, Potential pharmacokinetic basis for zolpidem dosing in children with sleep difficulties, Clin Pharmacol Ther, 83, 551, 10.1038/sj.clpt.6100380 Najib, 2006, Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia, Clin Ther, 28, 491, 10.1016/j.clinthera.2006.04.014 Roth, 2005, An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia, Sleep Med, 6, 487, 10.1016/j.sleep.2005.06.004 Walsh, 2007, Nightly treatment of primary insomnia with eszopiclone for six months: Effect on sleep, quality of life, and work limitations, Sleep, 30, 959, 10.1093/sleep/30.8.959 Guilleminault, 2000, Narcolepsy in children: A practical guide to its diagnosis, treatment and follow-up, Paediatr Drugs, 2, 1, 10.2165/00148581-200002010-00001 Taheri, 2002, The role of hypocretins (orexins) in sleep regulation and narcolepsy, Annu Rev Neurosci, 25, 283, 10.1146/annurev.neuro.25.112701.142826 Ripley, 2001, CSF hypocretin/orexin levels in narcolepsy and other neurological conditions, Neurology, 57, 2253, 10.1212/WNL.57.12.2253 Mignot, 2002, The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias, Arch Neurol, 59, 1553, 10.1001/archneur.59.10.1553 Littner, 2001, Practice parameters for the treatment of narcolepsy: An update for 2000, Sleep, 24, 451, 10.1093/sleep/24.5.603 Morgenthaler, 2007, Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin, Sleep, 30, 1705, 10.1093/sleep/30.12.1705 Wise, 2007, Treatment of narcolepsy and other hypersomnias of central origin, Sleep, 30, 1712, 10.1093/sleep/30.12.1712 Mitler, 2002, Benefits and risks of pharmacotherapy for narcolepsy, Drug Saf, 25, 791, 10.2165/00002018-200225110-00004 Tafti, 2003, Pharmacogenomics in the treatment of narcolepsy, Pharmacogenomics, 4, 23, 10.1517/phgs.4.1.23.22590 Amiri, 2008, Modafinil as a treatment for Attention-Deficit/Hyperactivity Disorder in children and adolescents: A double blind, randomized clinical trial, Prog Neuropsychopharmacol Biol Psychiatry, 32, 145, 10.1016/j.pnpbp.2007.07.025 Wigal, 2006, Efficacy and safety of modafinil film-coated tablets in children and adolescents with or without prior stimulant treatment for attention-deficit/hyperactivity disorder: Pooled analysis of 3 randomized, double-blind, placebo-controlled studies, Prim Care Companion J Clin Psychiatry, 8, 352 Swanson, 2006, Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: Results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation, J Clin Psychiatry, 67, 137, 10.4088/JCP.v67n0120 Biederman, 2005, Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: Results of a randomized, double-blind, placebo-controlled, flexible-dose study, Pediatrics, 116, e777, 10.1542/peds.2005-0617 2003, A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy, Sleep, 26, 31 Borgen, 2002, Sodium oxybate (GHB) for treatment of cataplexy, Pharmacotherapy, 22, 798, 10.1592/phco.22.9.798.34063 2002, A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy, Sleep, 25, 42 Robinson, 2007, Sodium oxybate: A review of ts use in the management of narcolepsy, CNS Drugs, 21, 337, 10.2165/00023210-200721040-00007 Fuller, 2004, The Xyrem risk management program, Drug Saf, 27, 293, 10.2165/00002018-200427050-00002 Xyrem, 2002, Date-rape drug approved for cataplexy, Nursing, 32, 24 Scharf, 1998, Pharmacokinetics of gammahydroxybutyrate (GHB) in narcoleptic patients, Sleep, 21, 507, 10.1093/sleep/21.5.507 Mignot, 1993, Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers, Psychopharmacology, 113, 76, 10.1007/BF02244337 Nishino, 1993, Further characterization of the alpha-1 receptor subtype involved in the control of cataplexy in canine narcolepsy, J Pharmacol Exp Ther, 264, 1079 Marcus, 1995, Supplemental oxygen during sleep in children with sleep-disordered breathing, Am J Respir Crit Care Med, 152, 1297, 10.1164/ajrccm.152.4.7551385 Marcus, 2001, Sleep-disordered breathing in children, Am J Respir Crit Care Med, 164, 16, 10.1164/ajrccm.164.1.2008171 Marcus, 1995, Use of nasal continuous positive airway pressure as treatment of childhood obstructive sleep apnea, J Pediatr, 127, 88, 10.1016/S0022-3476(95)70262-8 Hudgel, 1998, Pharmacologic treatment of sleep-disordered breathing, Am J Respir Crit Care Med, 158, 691, 10.1164/ajrccm.158.3.9802019 Thornton, 1996, Nonsurgical management of the obstructive sleep apnea patient, J Oral Maxillofac Surg, 54, 1103, 10.1016/S0278-2391(96)90170-6 Brouillette, 2001, Efficacy of fluticasone nasal spray for pediatric obstructive sleep apnea, J Pediatr, 138, 838, 10.1067/mpd.2001.114474 Marcus, 2001, Nasal steroids as treatment for obstructive sleep apnea: Don't throw away the scalpel yet, J Pediatr, 138, 795, 10.1067/mpd.2001.116063 Kheirandish, 2006, Intranasal steroids and oral leukotriene modifier therapy in residual sleep-disordered breathing after tonsillectomy and adenoidectomy in children, Pediatrics, 117, e61, 10.1542/peds.2005-0795 Picchietti, 2007, Restless legs syndrome: Prevalence and impact in children and adolescents—The Peds REST study, Pediatrics, 120, 253, 10.1542/peds.2006-2767 Picchietti DL, Stevens HE: Early manifestations of restless legs syndrome in childhood and adolescence. Sleep Med 2007 [Epub ahead of print] Mohri I, Kato-Nishimura K, Tachibana N, et al: Restless legs syndrome (RLS): An unrecognized cause for bedtime problems and insomnia in children. Sleep Med 2007 [Epub ahead of print] Picchietti, 1999, Further studies on periodic limb movement disorder and restless legs syndrome in children with attention-deficit hyperactivity disorder, Mov Disord, 14, 1000, 10.1002/1531-8257(199911)14:6<1000::AID-MDS1014>3.0.CO;2-P Hening, 1999, The treatment of restless legs syndrome and periodic limb movement disorder, Sleep, 22, 970 Picchietti, 2007, Is iron deficiency an underlying cause of pediatric restless legs syndrome and of attention-deficit/hyperactivity disorder?, Sleep Med, 8, 693, 10.1016/j.sleep.2007.06.007 Patrick, 2007, Restless legs syndrome: Pathophysiology and the role of iron and folate, Altern Med Rev, 12, 101 Konofal, 2007, Impact of restless legs syndrome and iron deficiency on attention-deficit/hyperactivity disorder in children, Sleep Med, 8, 711, 10.1016/j.sleep.2007.04.022 Dosman, 2007, Children with autism: Effect of iron supplementation on sleep and ferritin, Pediatr Neurol, 36, 152, 10.1016/j.pediatrneurol.2006.11.004 Beard, 2004, Iron status and periodic limb movements of sleep in children: A causal relationship?, Sleep Med, 5, 89, 10.1016/j.sleep.2003.12.002 Simakajornboon, 2003, Periodic limb movements in sleep and iron status in children, Sleep, 26, 735, 10.1093/sleep/26.6.735 Allen, 2001, MRI measurement of brain iron in patients with restless legs syndrome, Neurology, 56, 263, 10.1212/WNL.56.2.263 Littner, 2004, Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder, Sleep, 27, 557, 10.1093/sleep/27.3.557 Chesson, 1999, Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder, Sleep, 22, 961, 10.1093/sleep/22.7.961 Walters, 2000, Dopaminergic therapy in children with restless legs/periodic limb movements in sleep and ADHD, Pediatr Neurol, 22, 182, 10.1016/S0887-8994(99)00152-6 Earley, 1996, Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients, Sleep, 19, 801, 10.1093/sleep/19.10.801 Allen, 1996, Augmentation of the restless legs syndrome with carbidopa/levodopa, Sleep, 19, 205, 10.1093/sleep/19.3.205 Burg, 2002 Walters, 1987, Clinical presentation and neuropharmacology of restless legs syndrome, Clin Neuropharmacol, 10, 225, 10.1097/00002826-198706000-00004 Guilleminault, 1993, Dopaminergic treatment of restless legs and rebound phenomenon, Neurology, 43, 445, 10.1212/WNL.43.2.445 Allen, 2001, Restless legs syndrome: A review of clinical and pathophysiologic features, J Clin Neurophysiol, 18, 128, 10.1097/00004691-200103000-00004 Earley, 2001, CSF dopamine, serotonin, and biopterin metabolites in patients with restless legs syndrome, Mov Disord, 16, 144, 10.1002/1531-8257(200101)16:1<144::AID-MDS1009>3.0.CO;2-F Earley, 2000, Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome, Neurology, 54, 1698, 10.1212/WNL.54.8.1698 Allen, 2002, Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome, Neurology, 59, 639, 10.1212/WNL.59.4.639 Oertel, 2007, Efficacy of pramipexole in restless legs syndrome: A six-week, multicenter, randomized, double-blind study (effect-RLS study), Mov Disord, 22, 213, 10.1002/mds.21261 Allen RP, Ritchie SY. Clinical efficacy of ropinirole for restless legs syndrome is not affected by age at symptom onset. Sleep Med 2007 [Eput ahead of print] Quilici S, Abrams KR, Nicolas A, et al: Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. Sleep Med 2008 [Epub ahead of print] Montplaisir, 1999, Restless legs syndrome improved by pramipexole: A double-blind randomized trial, Neurology, 52, 938, 10.1212/WNL.52.5.938